The US FDA’s final guidance on the limited population pathway for antibacterial and antifungal drugs (LPAD) contains no major substantive changes from a draft version but provides additional clarity on eligible indications and populations.
In addition, the guidance gives more detail about the processes for submitting promotional materials, and for seeking termination